Cognito Therapeutics Announces Oral Presentation on Spectris Therapy Open-Label Study Data in Alzheimer's Disease at AD/PD 2024

Cognito Therapeutics, a leader in technology-based therapeutic interventions for neurodegenerative diseases, announced today it has been selected to present data from an open label extension study evaluating its potential novel therapy, Spectris, in Alzheimer's Disease (AD), as an oral presentation at the AD/PDtm 2024 International Conference on Alzheimer's and Parkinson's Disease, held March 5-9, 2024 in Lisbon, Portugal.

"We are excited to present the results from our open label extension study at AD/PD 2024, showcasing the long-term treatment effect of our potential disease-modifying novel therapy, Spectris, over an 18-month period," said Brent Vaughan, CEO of Cognito Therapeutics. "Our findings further evaluate the safety of longer-term treatment, and support the efficacy results from our OVERTURE clinical trial, a randomized, double-blind, sham-controlled clinical trial, which showed significant slowing of disease progression and preservation of both brain structure and function in individuals with AD."

Details of the oral presentation are as follows:

Presentation Title: OVERTURE OPEN LABEL EXTENSION DATA ARE CONSISTENT WITH DISEASE MODIFICATION AND SUPPORT EARLY TREATMENT

Session Type: Symposium

Date: Saturday, March 9, 2024

Lecture Time: 10:10 ? 10:25 am

Location: Room Auditorium VIII

Presenter: Ralph Kern, M.D., MHSc, Chief Medical Officer of Cognito Therapeutics

The OVERTURE (NCT03556280) clinical trial (RCT), a randomized, double-blind, sham-controlled clinical trial, was designed to evoke gamma oscillations using Cognito's potential novel therapy, Spectris, in mild to moderate AD and included a 12-month open label extension (OLE). OLE data was analyzed using a delayed start study design to demonstrate evidence of Spectris' potential disease modifying (DM) therapy.

Participants who completed the six-month RCT were eligible to receive 1-hour daily treatment for an additional 12 months in the OLE. An ?as treated' population was evaluated for safety, adherence, and efficacy (ADCS-ADL and MRI measures). A DM analysis was performed using the off-treatment period between the RCT and OLE along with regression modeling that controlled for baseline age, ADCS-ADL and MMSE.

For more information about the AD/PD 2024 conference, visit: https://adpd.kenes.com.

About Cognito Therapeutics

Cognito Therapeutics is a late clinical-stage neurotechnology company dedicated to the development of transformative disease-modifying therapies for neurodegenerative diseases. Cognito's proprietary approach targets dysregulated network activity in the brain and has shown meaningful outcomes in Alzheimer's patients. Cognito's lead product, Spectris, employs a proprietary non-invasive method designed to evoke increased gamma frequency brain activity using auditory and visual neuromodulation to slow the rate of brain atrophy and loss of brain function. Cognito's mission is to develop a new class of technology-based therapeutic interventions to transform the lives of patients with neurodegenerative diseases. Cognito is headquartered in Cambridge, MA. For more information, visit www.cognitotx.com.